Search

Your search keyword '"Papi, Laura"' showing total 275 results

Search Constraints

Start Over You searched for: Author "Papi, Laura" Remove constraint Author: "Papi, Laura" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
275 results on '"Papi, Laura"'

Search Results

1. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

2. Heterozygosity for loss-of-function variants in LZTR1 is associated with isolated multiple café-au-lait macules

5. A novel CDKN2A in-frame deletion associated with pancreatic cancer-melanoma syndrome

6. ERN GENTURIS clinical practice guidelines for the diagnosis, treatment, management and surveillance of people with schwannomatosis

7. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

8. A Clinical Workflow for Cost-Saving High-Rate Diagnosis of Genetic Kidney Diseases

10. When to test fetuses for RASopathies? Proposition from a systematic analysis of 352 multicenter cases and a postnatal cohort

11. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

12. Epigenomic, genomic, and transcriptomic landscape of schwannomatosis

13. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

14. Expanding the mutational spectrum of LZTR1 in schwannomatosis

15. Identification of six new susceptibility loci for invasive epithelial ovarian cancer.

16. Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

17. Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk

18. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.

19. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.

20. Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia

22. Central, Eastern, and Southeastern European Countries' Convergence: A Look at the Past and Considerations for the Future

24. Supplementary Tables S1-S3 from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

25. Supplementary Figure S1. from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

26. Data from LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL

27. Supplementary Table 2 from Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

28. Supplementary Table 3 from Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

29. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2.

30. Correction to: Epigenomic, genomic, and transcriptomic landscape of schwannomatosis

31. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

32. A mosaic pattern of INI1/SMARCB1 protein expression distinguishes Schwannomatosis and NF2-associated peripheral schwannomas from solitary peripheral schwannomas and NF2-associated vestibular schwannomas

33. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

34. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3

35. LZTR1 mutation mediates oncogenesis through stabilization of EGFR and AXL

36. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation

38. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis:An international consensus recommendation

39. Assessment of the InSiGHT Interpretation Criteria for the Clinical Classification of 24 MLH1 and MSH2 Gene Variants

40. FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor

41. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation

42. Germline mutations in MSH2 and ATM gene in patients with GIST (gastrointestinal stromal tumor) and second epitelial tumors.

43. Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

44. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

45. Characterization of the cancer spectrum in men with germline BRCA1 and BRCA2 pathogenic variants

46. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

47. The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

48. Characterization of the Cancer Spectrum in Men with Germline BRCA1 and BRCA2 Pathogenic Variants:Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

50. EPCO-04. GENOMIC AND EPIGENOMIC HALLMARKS OF SCHWANNOMATOSIS SCHWANNOMAS

Catalog

Books, media, physical & digital resources